Business & Profession

For all of us associated with healthcare, it should be apparent that our world is on the cusp of a significant change.

Sitting Down With Carrie MacEwen, Consultant Ophthalmologist at Ninewells Hospital, Dundee, Scotland, and President-Elect of the UK Royal College of Ophthalmologists

The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?

Americans love their cars and in many places you’re virtually stranded if you don’t drive. So does vision loss stop elderly Americans from driving?

The pupil of the eye is dark, and the cornea highly reflective – it acts as a mirror. Combine this with high resolution photography, and you get a whole new vista.

The media have been building up “eyeball jewelry” as a potential craze, but the evidence suggests otherwise

Gene therapy for ocular disease will soon be available. Stem cell therapies too. They may be able to cure the currently untreatable, but at what price? And will anyone pay it?

Expert opinion: infection prevention & treatment in photorefractive surgery patients.

Jim discusses his background, leadership style and his vision for Oraya's future with us.

Patients need to know what their ophthalmologist actually ‘does’, and what to expect when they are referred.